2007'02.01.Thu
TAXUS ATLAS Trial Supports Excellent Deliverability and Proven Outcomes of TAXUS(R) Liberte(TM) Stent System

PR
May 17, 2006

Boston Scientific's Second Generation Stent Compares Favorably to Market Leading TAXUS Express2(TM) Stent System, Even with More Complex Lesions
NATICK, Mass., and PARIS, May 17 /Xinhua-PRNewswire/ -- Boston Scientific Corporation (NYSE: BSX) today announced nine-month data from its TAXUS ATLAS clinical trial. The results confirmed safety and efficacy and demonstrated the excellent deliverability of the TAXUS(R) Liberte(TM) paclitaxel-eluting stent system compared to the TAXUS Express(TM) *and TAXUS Express2(TM) paclitaxel-eluting stent system. The Company made the announcement at the annual Paris Course on Revascularization (EuroPCR) held this week in Paris. "The TAXUS ATLAS trial expands one of the largest DES data collections and extends the consistent clinical outcomes seen in the TAXUS clinical program to a new stent platform," said Mark A. Turco M.D., F.A.C.C., Director, Center for Cardiac and Vascular Research, Washington Adventist Hospital, Takoma Park, MD, and trials co-principle investigator. "The TAXUS Liberte stent provides improved deliverability and conformability and the ATLAS trial results support excellent performance in complex lesions more consistent with evolving clinical practice patterns." The TAXUS ATLAS trial is a global, multi-center pivotal study comparing the TAXUS
Post your Comment
広告
ブログ内検索
アーカイブ
カウンター